CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Legend Biotech Corporation ( (LEGN) ) has released its Q3 earnings. Here is a breakdown of the information Legend Biotech Corporation presented ...

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week.

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech reports third quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...